NCT00746590终止2 期
A Phase 2 Study of the Anti-tumour Activity and Safety of Prolarix™ in Hepatocellular Carcinoma (HCC)
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 1
- 试验地点
- 1
- 主要终点
- Overall Best Tumor Response Rate (Proportion of Subjects With Complete or Partial Response) as Defined by Modified RECIST
研究概览
简要总结
This an open-label study designed to evaluate the anti-tumour activity and safety of Prolarix in subjects with advanced hepatocellular carcinoma.
Prolarix is a chemotherapy comprised of tretazicar as prodrug and caricotamide as co-substrate for the endogenous enzyme, NQO2.
详细描述
The primary objective of this study is to evaluate the anti-tumour effects of treatment with Prolarix in subjects with advanced HCC (Child-Pugh A and B only).
All subjects will receive an IV infusion of Prolarix once every 21 days until disease progression is observed.
Subjects will have CT scans for tumour measurements before starting treatment with Prolarix and every 6 weeks until disease progression.
Subjects will undergo evaluation for safety (adverse events, vital signs, clinical laboratory measurements, weight, ECG) every 21 days until disease progression.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject must be at least 18 years of age.
- •Subject must have a histologic or cytologic diagnosis of HCC and be considered unsuitable for resection or other potentially curative options (eg, liver transplant, curative radiofrequency ablation).
- •Subject must have a measurable lesion by RECIST on CT scan in at least one site which has not received radiation or any other local therapy [eg, transcatheter arterial chemoembolisation (TACE), radiofrequency ablation, local injection]. (Note: Subjects who have received local therapies will be allowed to participate, provided that they have a target lesion which has not been subjected to local therapy. Subjects who have received TACE must have a target lesion outside of the vascular territory subjected to chemoembolisation.)
- •Subject has an Eastern Cooperative Oncology Group (ECOG) Performance status of 0 or
- •Subject has had no other active malignancy within the past three years [other than non melanomatous skin cancer or carcinoma in situ (CIS) of the breast, bladder, or uterine cervix. Subjects with Ta (non-invasive papillary carcinoma) or Tis (sessile carcinoma in situ) bladder cancer are allowed].
- •Subject has a minimum life expectancy of at least three months as determined by the investigator.
- •Subject has adequate bone marrow function (ie, haemoglobin ≥9 g/dL, granulocytes ≥1500/mm3, platelets ≥75,000/mm3).
- •Prothrombin time (PT)-international normalised ratio (INR) ≤2.3 or PT ≤6 seconds above control. (Note: Subjects who are being therapeutically anticoagulated with an agent such as warfarin or heparin will be allowed to participate provided that their INR is between 2.0 and 3.
- •Subject has adequate renal function (ie, serum creatinine is normal or calculated creatinine clearance is ≥60 mL/min).
- •Subject has adequate hepatic function (ie, bilirubin ≤2x upper limit of normal (ULN); AST ALT, and alkaline phosphatase ≤5xULN). (Also see exclusion for Child-Pugh class C below).
- •Male subjects and females of childbearing potential must agree to use an adequate method of contraception from the time of initiation of treatment through study participation and for 3 months after release from the study.
- •Subject is able to give informed consent.
排除标准
- •Any prior or current systemic pharmacotherapy for HCC (cytotoxic, targeted or biologic). (Note: TACE is not considered to be systemic pharmacotherapy for the purpose of this study).
- •Subject has an absolute contraindication to receiving CT contrast media. (Note: Subjects with a history of minor contrast reactions may be pre-medicated prior to contrast administration in accordance with local or institutional practice).
- •Subject has Child-Pugh Class C hepatic impairment.
- •Subject has received an investigational drug within 30 days of enrolment in the study.
- •Females of childbearing potential unless using adequate contraception.
- •Pregnant or lactating females.
- •Major variceal bleeding in the last 30 days.
- •Subjects with a known history of human immunodeficiency virus (HIV) infection.
研究组 & 干预措施
1
Experimental
干预措施: Prolarix (tretazicar co-administered with caricotamide) (Drug)
结局指标
主要结局
Overall Best Tumor Response Rate (Proportion of Subjects With Complete or Partial Response) as Defined by Modified RECIST
时间窗: every 6 weeks until progression
次要结局
- Changes in Laboratory Measurements(Baseline and every 3 weeks until progression)
- Changes in Alpha Fetoprotein(Baseline, every 3 weeks until progression)
- Disease Control Rate Defined as the Proportion of Subjects With Either Complete or Partial Response or Stable Disease(Approximately 12 weeks or more after first treatment with Prolarix)
- Time to Tumour Progression(Every 3 weeks until progression)
- Post-treatment Changes in the Amount of Contrast-enhancing and Non-contrast-enhancing Tumour(Every 6 weeks until progression)
- Adverse Events(Until progression)
研究者
研究点 (1)
Loading locations...
相似试验
撤回
2 期
Study of an Individualized Vaccine Targeting Neoantigens in Combination With Immune Checkpoint Blockade for Patients With Colon CancerColonic NeoplasmsColorectal NeoplasmsNCT05456165Gritstone bio, Inc.1
已完成
2 期
Efficacy/Safety of Imprime PGG® Injection With Bevacizumab and Paclitaxel/Carboplatin in Patients With Untreated Advanced Non-Small Cell Lung Cancer (NSCLC)Non-Small Cell Lung CancerNCT00874107HiberCell, Inc.90
已完成
2 期
A Study of Telatinib in Combination With Chemotherapy in Subjects With Advanced Gastric CancerGastric CancerNCT00952497ACT Biotech, Inc48
招募中
2 期
A Phase 2 Clinical Study of Combination Therapy With ABSK043 and FirmonertinibNon-Small Cell Lung Cancer With EGFR MutationNCT06668103Abbisko Therapeutics Co, Ltd54
招募中
1 期
A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell MalignanciesB-cell MalignancyRelapsed CancerRefractory CancerB-cell LymphomaNCT06634589BeOne Medicines80